http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-104693190-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-13 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D409-10 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-381 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D409-10 |
| filingDate | 2013-12-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2017-05-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2017-05-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-104693190-B |
| titleOfInvention | Crystal form B of compound as well as preparation method and application thereof |
| abstract | The invention belongs to the technical field of medicines and particularly discloses a crystal form B of a deoxyC-glucoside SGLT2 inhibitor 4-(6-deoxy-beta-D-glucopyranosyl)-2-[5-(4-fluorophenyl)thiophene-2-methyl]-1-methylbenzene (CD-6) as well as a preparation method and application thereof. The values of the characteristic absorption peaks (2theta) of powder X-ray diffraction of the crystal form are 3.30, 5.34, 6.04, 6.58, 8.10, 8.90, 10.76, 11.60, 12.08, 13.18, 13.90, 14.74, 16.18, 16.88, 18.10, 19.38, 20.52, 21.14, 22.02, 23.36 and 24.50, wherein the measuring error of 2theta is +/-0.2. The crystal form has the characteristics of stable apparent condition, capability of further improving the purity of the compound, stability in preservation, and the like, and has the characteristic of direct supply of active pharmaceutical ingredients. A chemical structural formula of the compound is as shown in the specification. |
| priorityDate | 2013-12-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 45.